TriSalus Life Sciences (TLSI) Total Liabilities (2020 - 2026)

TriSalus Life Sciences has reported Total Liabilities for 7 years, with the latest figure at $58.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 7.66% year-over-year to $58.2 million; the trailing twelve-month figure through Mar 2026 stood at $58.2 million (down 7.66% YoY), and the FY2025 full-year result was $69.2 million, up 38.76% from the prior year.
• Total Liabilities for Q1 2026 stood at $58.2 million, down from $69.2 million in the prior quarter.
• The five-year high for Total Liabilities was $69.2 million in Q4 2025, with the low at $12.0 million in Q2 2022.
• Historically, Total Liabilities has averaged $41.2 million across 5 years, with a median of $49.9 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities sank 46.89% — and 2024, when it soared 271.65%.
• TriSalus Life Sciences' Total Liabilities stood at $34.3 million in 2022, then soared by 50.54% to $51.7 million in 2023, then slipped by 3.48% to $49.9 million in 2024, then surged by 38.76% to $69.2 million in 2025, then declined by 15.93% to $58.2 million in 2026.
• The last three Total Liabilities figures came in at $58.2 million (Q1 2026), $69.2 million (Q4 2025), and $63.2 million (Q3 2025), per Business Quant data.